Oculis Holding AG Dossier
Qualitative Analysis
Business overview
Oculis Holding AG (NASDAQ: OCS / XICE: OCS) is a Switzerland-based, clinical-stage biopharmaceutical company dedicated to developing innovative topical treatments (eye drops) for ophthalmic and neuro-ophthalmic diseases. The company leverages its proprietary OPTIREACH technology to deliver therapeutics to both the front and back of the eye non-invasively. Its pipeline is anchored by Privosegtor (OCS-05), a disease-modifying neuroprotective candidate targeting acute optic neuritis (AON) and other neuro-ophthalmic disorders, and Licaminlimab (OCS-02), a topical anti-TNFα biologic candidate being developed for dry eye disease (DED) using a genotype-driven precision medicine approach.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing OCS-01, a novel high-concentration topical eye drop formulation of dexamethasone utilizing OPTIREACH technology, through Phase 3 DIAMOND trials for Diabetic Macular Edema (DME) to offer a non-invasive alternative to invasive eye injections.
Expected impact: Provides a first-in-class topical treatment option for DME, addressing a multi-billion dollar market opportunity.
Evaluating Licaminlimab (OCS-02), a novel topical anti-TNFα antibody, in the PREDICT-1 registrational trial using a biomarker-driven, genotype-based approach to target Dry Eye Disease (DED).
Expected impact: Establishes the first precision medicine paradigm in ophthalmology, improving patient outcomes and reducing trial-and-error prescribing.
Advancing Privosegtor (OCS-05), a first-in-class disease-modifying neuroprotective small molecule, into the PIONEER registrational program for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION).
Expected impact: Addresses a potential market opportunity of over $7 billion in the U.S. alone, backed by FDA Breakthrough Therapy and EMA PRIME designations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Oculis licensed the novel topical anti-TNFα antibody, renamed Licaminlimab (OCS-02), for ophthalmic indications, which now serves as one of Oculis's core late-stage clinical assets.
Terms: Under the agreement dated December 19, 2018, Oculis acquired exclusive global rights to develop and commercialize the asset.
Oculis secured exclusive global rights to develop and commercialize Privosegtor (OCS-05, formerly ACT-01), a disease-modifying neuroprotective agent targeting acute optic neuritis and other neuro-ophthalmic disorders.
Terms: Under the agreement dated January 29, 2022, Oculis paid upfront licensing fees and is responsible for development-related costs and milestone payments (including CHF 1.1 million capitalized in Q4 2024 upon Phase 2 completion and IND clearance).